<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829178</url>
  </required_header>
  <id_info>
    <org_study_id>91-03-33-18878</org_study_id>
    <nct_id>NCT01829178</nct_id>
  </id_info>
  <brief_title>Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma</brief_title>
  <official_title>Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatin is a potent chemotherapeutic agent that has been widely used to treat many solid&#xD;
      tumours. acute renal failure, despite conservative fluid and electrolyte management,&#xD;
      frequently reported adverse event and limiting cisplatin use. Silymarin, a flavonolignan&#xD;
      complex isolated from Silybum marianum, has a strong antioxidant, hepatoprotective,&#xD;
      anticancer and in animal model nephroprotective properties. Neutrophil gelatinase-associated&#xD;
      lipocalin (NGAL) protein is a promising biomarker to detect acute kidney injury due to&#xD;
      cisplatin. Milk thistle extract inhibitory effects on epidermal growth factor receptor,&#xD;
      vascular endothelial growth factor and insulin-like growth factor-I have shown in the&#xD;
      previous in-vitro studies.The aim of present study,a randomized double-blind placebo-&#xD;
      controlled clinical trial, to investigate the therapeutic effect of silymarin on cisplatin&#xD;
      induced nephrotoxicity and it's impact on chemotherapy. Fifty-eight patients with diagnosed&#xD;
      upper gastrointestinal tract carcinomas randomized to silymarin (420mg) or placebo plus&#xD;
      chemotherapy [cisplatin 50-60 mg/m2, 5-fluorouracil mg/m2, docetaxel 60-80 mg/m2 every 21&#xD;
      days] for 63 day after inclusion. serum creatinin, blood urea nitrogen (BUN), serum and urine&#xD;
      electrolyte will be measured daily during chemotherapy.&#xD;
&#xD;
      changes in urine NGAL, serum vascular endothelial growth factor (VEGF)and caspase activity&#xD;
      assessed up to 64 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will look for possible protective effects silymarin on kidney injury in patients&#xD;
      receiving cisplatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine concentration of NGAL</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>All subject receive silymarin at dose of 420mg or placebo in three dose for 65 consecutive day, urine NGAL concentration will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in VEGF Serum concentration</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>To assess interaction between silymarin and cancer chemotherapy serum vascular endothelial growth factor will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue activity of caspase 3</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>To assess interaction between silymarin and cancer chemotherapy Tissue activity of caspase 3will be measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Upper GI Cancer</condition>
  <condition>Cisplatin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exprimental: Silymarin and chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>Silymarin 420 mg in 3 divided dose plus standard chemotherapy</description>
    <arm_group_label>Exprimental: Silymarin and chemotherapy</arm_group_label>
    <other_name>Milk thistle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets: 420 mg in 3 divided dose</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>Identical inert tablet to mimic silymarin (140 mg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Exprimental: Silymarin and chemotherapy</arm_group_label>
    <other_name>Cisplatin</other_name>
    <other_name>fluorouracil</other_name>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt;18 years&#xD;
&#xD;
          -  diagnosed&#xD;
&#xD;
          -  measurable upper gastrointestinal adenocarcinoma&#xD;
&#xD;
          -  swallow problem&#xD;
&#xD;
          -  would like to participate in the study&#xD;
&#xD;
          -  Glomerular filtration rate(GFR)&gt;45ml/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  end stage renal disease&#xD;
&#xD;
          -  requiring dialysis&#xD;
&#xD;
          -  post transplantation&#xD;
&#xD;
          -  receiving contrast media during last 72 hours&#xD;
&#xD;
          -  chronic use of corticosteroids&#xD;
&#xD;
          -  chronic use of angiotensin-converting enzyme inhibitor(ACEI )&#xD;
&#xD;
          -  untreated hypo-and hyperthyroidism&#xD;
&#xD;
          -  ejection fraction&lt;60%&#xD;
&#xD;
          -  active urinary tract infection&#xD;
&#xD;
          -  iver disease ( five fold increase of liver enzyme in asymptomatic or 3 fold increase&#xD;
             in symptomatic&#xD;
&#xD;
          -  use of other nephrotoxic agents such as aminoglycoside, amphotericin&#xD;
&#xD;
          -  karnofsky performance status &lt;70&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simin Dashti-Khavidaki, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tehran University of Medical Science</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cisplatin</keyword>
  <keyword>nephrotoxicity</keyword>
  <keyword>antioxidant</keyword>
  <keyword>urine neutrophil gelatinase-associated lipocalin (NGAL)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

